BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, March 19, 2026
Home » Authors » Randy Osborne

Articles by Randy Osborne

Virogenomics New Spin-Off Artielle: $11M For MS Work

June 29, 2004
By Randy Osborne

Alteon's Stock Sale Raises Up To $12.8M For Phase IIs

June 29, 2004
By Randy Osborne

Tarceva Blockbuster'May Falter In Second Line, But There's Hope

June 28, 2004
By Randy Osborne

Two Players In Tricky HCV Race Gain Cash As Virus Marches On

June 21, 2004
By Randy Osborne
One of the sneakier and more challenging diseases is the liver condition brought about by the dreaded hepatitis C virus, which chronically afflicts about 2.7 million people in the U.S. - each at risk of fibrosis, cirrhosis, liver cancer, liver failure, or all of the above, and ultimately death.
Read More

ChemoCentryx Raises $33M For Chemokine-Target Drugs

June 18, 2004
By Randy Osborne

StemCells Placement Raises $20M For Batten Drug, More

June 18, 2004
By Randy Osborne

Metabasis Prices IPO: $35M Helps Liver Product Pipeline

June 17, 2004
By Randy Osborne

Vertex's Deal With Mitsubishi: $33M To Boost HCV Research

June 15, 2004
By Randy Osborne

Idun Placement Gets $27M To Progress Liver Therapy

June 15, 2004
By Randy Osborne

In-Licensing Strategy Perilous; Phase II Drugs Not Safe, Either

June 14, 2004
By Randy Osborne
Previous 1 2 … 408 409 410 411 412 413 414 415 416 … 469 470 Next

Popular Stories

  • Today's news in brief

    BioWorld

    BioWorld briefs for March 19, 2026.

  • Art concept for targeting the brain

    Precision psychiatry beyond, or before, biomarkers

    BioWorld
    There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
  • Illustration of a motor neuron

    Keros reports beneficial effects of RKER-065 in ALS model

    BioWorld Science
    Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 17, 2026
  • First-in-class POLG activator restores mtDNA across mutations

    BioWorld Science
    Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing